17.09.2014 13:19:49
|
Concert Pharma Begins Phase 1 Trial Of CTP-730 - Quick Facts
(RTTNews) - Concert Pharmaceuticals, Inc.(CNCE) Wednesday said it has begun Phase 1 clinical study of CTP-730, a new product candidate developed under collaboration with Celgene Corp.(CELG) The Phase 1 clinical trial is a randomized, double-blind, single ascending dose for evaluating the safety, tolerability and pharmacokinetics of CTP-730. The study is expected to enroll up to 40 healthy subjects. The trial will also assess multiple ascending doses of CTP-730 and is expected to be completed in 2015.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Concert Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |